Results

1–3 of 3 results for Vrinda S. Hershberger

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Real-World Treatment Patterns in Patients With Macular Edema Due to Retinal Vein Occlusion
Vrinda S. Hershberger, MD, PhD
Annual Meeting Talks
2020
Simultaneous Inhibition of Ang-2 and VEGF-A With Faricimab in DME: Additional Anatomical and Durability Outcomes From the BOULEVARD Phase 2 Trial
Vrinda S. Hershberger, MD, PhD
Annual Meeting Talks
2019